Richard Brudnick

Richard H.
Brudnick is currently serving as an Independent Non-Executive Director at InflaRx NV since 2019, an Independent Director at Scholar Rock Holding Corp.
since 2023, an Independent Director at Volition America, Inc. since 2021, a Director at Tamarix Pharma Ltd since 2021, a Venture Advisor at Israel Biotech Fund since 2018, and the Chief Business Officer at Prime Medicine, Inc. since 2022.
Previously, Mr. Brudnick held the position of President & Chief Executive Officer at James Brudnick Co., Inc. from 1984 to 1998.
He also served as an Independent Director at VolitionRX Ltd.
from 2021 to 2023, Senior VP-Corporate Development & Strategy at Biogen, Inc. from 2014 to 2016, Chief Business Officer & Head-Strategy at Codiak BioSciences, Inc. from 2018 to 2022, and Executive Vice President-Business Development at Bioverativ, Inc. from 2016 to 2018.
Mr. Brudnick obtained his undergraduate degree from Massachusetts Institute of Technology in 1978.
He also holds an MBA from MIT Sloan School of Management, which he earned in 1980.
Additionally, he has completed undergraduate and graduate studies at MIT Sloan School of Management.